Factors Associated with Incomplete Resection for Large, Locally Invasive Non-small Cell Lung Cancer

Overview

Journal J Thorac Dis

Publisher AME Publishing Company

Specialty Pulmonary Medicine

Date 2024 Jun 17

PMID 38883676

Authors

Whitney S Brandt

Zhizhou Yang

Brendan T Heiden

Pamela P Samson

Daniel Morgensztern

Saiama N Waqar

Bryan F Meyers

Ruben G Nava

G Alexander Patterson

Benjamin D Kozower

Varun Puri

Affiliations

Soon will be listed here.

Abstract

Background: Large, node-negative but locally invasive non-small cell lung cancer (NSCLC) is associated with increased perioperative risk but improved survival if a complete resection is obtained. Factors associated with positive margins in this population are not well-studied.

Methods: We performed a retrospective cohort study using National Cancer Database (NCDB) for adult patients with >5 cm, clinically node-negative NSCLC with evidence of invasion of nearby structures [2006-2015]. Patients were classified as having major structure involvement (azygous vein, pulmonary artery/vein, vena cava, carina/trachea, esophagus, recurrent laryngeal/vagus nerve, heart, aorta, vertebrae) or chest wall invasion (rib pleura, chest wall, diaphragm). Our primary outcome was to evaluate factors associated with incomplete resection (microscopic: R1, macroscopic: R2). Kaplan-Meier analysis and cox multivariable regression models were used to evaluate overall survival (OS), 90-day mortality, and factors associated with positive margins.

Results: Among 2,368 patients identified, the median follow-up was 33.8 months [interquartile range (IQR), 12.6-66.5 months]. Most patients were white (86.9%) with squamous cell histology (47.3%). Major structures were involved in 26.4% of patients and chest wall invasion was seen in 73.6%. Four hundred and seventy-eight patients (20.2%) had an incomplete resection. Multivariable analysis revealed that black race [hazard ratio (HR) 1.568, 95% confidence interval (CI): 1.109-2.218] and major structure involvement (HR 1.412, 95% CI: 1.091-1.827) was associated with increased risk of incomplete resection and surgery at an academic hospitals (HR 0.773, 95% CI: 0.607-0.984), adenocarcinoma histology (HR 0.672, 95% CI: 0.514-0.878), and neoadjuvant chemotherapy (HR 0.431, 95% CI: 0.316-0.587) were associated with decreased risk of incomplete resection. The 5-year OS was 43.7% in the entire cohort and 28.8% in patients with positive margins and 47.5% in patients with an R0 resection. Positive margin was also associated with a significantly higher 90-day mortality rate (9.9% versus 6.7%).

Conclusions: For patients with large, node-negative NSCLC invading nearby structures, R0 resection portends better survival. Treatment at academic centers, adenocarcinoma histology, and receipt of neoadjuvant chemotherapy are associated with R0 resection in this high-risk cohort.

References

Rusch V, Giroux D, Kraut M, Crowley J, Hazuka M, Winton T . Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Clin Oncol. 2007; 25(3):313-8. DOI: 10.1200/JCO.2006.08.2826. View

Osarogiagbon R, Lin C, Smeltzer M, Jemal A . Prevalence, Prognostic Implications, and Survival Modulators of Incompletely Resected Non-Small Cell Lung Cancer in the U.S. National Cancer Data Base. J Thorac Oncol. 2016; 11(1):e5-16. PMC: 4714753. DOI: 10.1016/j.jtho.2015.08.002. View

Galetta D, Spaggiari L . Atrial Resection without Cardiopulmonary Bypass for Lung Cancer. Thorac Cardiovasc Surg. 2019; 68(6):510-515. DOI: 10.1055/s-0039-1700563. View

Felip E, Altorki N, Zhou C, Csoszi T, Vynnychenko I, Goloborodko O . Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021; 398(10308):1344-1357. DOI: 10.1016/S0140-6736(21)02098-5. View

Provencio M, Nadal E, Insa A, Garcia-Campelo M, Casal-Rubio J, Domine M . Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020; 21(11):1413-1422. DOI: 10.1016/S1470-2045(20)30453-8. View

Towe C, Worrell S, Bachman K, Sarode A, Perry Y, Linden P . Neoadjuvant Treatment Is Associated With Superior Outcomes in T4 Lung Cancers With Local Extension. Ann Thorac Surg. 2020; 111(2):448-455. DOI: 10.1016/j.athoracsur.2020.05.084. View

Rosen J, Hancock J, Kim A, Detterbeck F, Boffa D . Predictors of mortality after surgical management of lung cancer in the National Cancer Database. Ann Thorac Surg. 2014; 98(6):1953-60. DOI: 10.1016/j.athoracsur.2014.07.007. View

Reardon E, Schrump D . Extended resections of non-small cell lung cancers invading the aorta, pulmonary artery, left atrium, or esophagus: can they be justified?. Thorac Surg Clin. 2014; 24(4):457-64. PMC: 6301020. DOI: 10.1016/j.thorsurg.2014.07.012. View

Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt W . The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016; 11(1):39-51. DOI: 10.1016/j.jtho.2015.09.009. View

10.

Jawitz O, Wang Z, Boffa D, Detterbeck F, Blasberg J, Kim A . The differential impact of preoperative comorbidity on perioperative outcomes following thoracoscopic and open lobectomies. Eur J Cardiothorac Surg. 2016; 51(1):169-174. DOI: 10.1093/ejcts/ezw239. View

11.

Lee C, Byun C, Lee J, Kim D, Cho B, Chung K . The prognostic factors of resected non-small cell lung cancer with chest wall invasion. World J Surg Oncol. 2012; 10:9. PMC: 3283516. DOI: 10.1186/1477-7819-10-9. View

12.

Xu K, Yang H, Ma W, Fan L, Sun B, Wang Z . Neoadjuvant immunotherapy facilitates resection of surgically-challenging lung squamous cell cancer. J Thorac Dis. 2022; 13(12):6816-6826. PMC: 8743415. DOI: 10.21037/jtd-21-1195. View

13.

Spigel D, Faivre-Finn C, Gray J, Vicente D, Planchard D, Paz-Ares L . Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022; 40(12):1301-1311. PMC: 9015199. DOI: 10.1200/JCO.21.01308. View

14.

Al-Ayoubi A, Flores R . Surgery for lung cancer invading the mediastinum. J Thorac Dis. 2016; 8(Suppl 11):S889-S894. PMC: 5124591. DOI: 10.21037/jtd.2016.06.71. View

15.

Spaggiari L, Leo F, Veronesi G, Solli P, Galetta D, Tatani B . Superior vena cava resection for lung and mediastinal malignancies: a single-center experience with 70 cases. Ann Thorac Surg. 2006; 83(1):223-9. DOI: 10.1016/j.athoracsur.2006.07.075. View

16.

Rami-Porta R, Bolejack V, Crowley J, Ball D, Kim J, Lyons G . The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2015; 10(7):990-1003. DOI: 10.1097/JTO.0000000000000559. View

17.

Rasing M, Peters M, Moreno A, Hofman E, Herder G, Welvaart P . Predicting Incomplete Resection in Non-Small Cell Lung Cancer Preoperatively: A Validated Nomogram. Ann Thorac Surg. 2020; 111(3):1052-1058. DOI: 10.1016/j.athoracsur.2020.05.165. View

18.

Sato K, Nakamura S, Kadomatsu Y, Ueno H, Kato T, Ozeki N . Neoadjuvant Therapy for Patients With Non-small Cell Lung Cancer Complicated With Chest Wall Invasion. Anticancer Res. 2022; 42(11):5539-5546. DOI: 10.21873/anticanres.16059. View